Dr Ujuwa Choukwa, a Virologist, has assured that vaccination against Tuberculosis
(TB) will expand the age-long fight against the disease.
Medical Research Institute “and if successful, it will go a long way in addressing the scourge.”
She said “a live attenuated vaccine in use for nearly a century called Bacillus Calmette-Guerin prevents severe disease in infants and young children,
but gives limited protection to adolescents and adults.
“Mid-stage testing has shown that Glaxo’s experimental shot can be effective in about half of people who get it for as long as three years.”
The virologist said that the vaccine would, hopefully, provide long-term protection against the disease.
According to her, as most people who are infected with Mycobacterium tuberculosis do not get TB, the believe is that infection confers some degree of protection.
“As a result, it is really exciting and thoughtful of the research institute to sponsor this vaccine,” she said.
She added that the new vaccine against tuberculosis would bring prevention of the deadly disease to Nigeria and other poor countries.
The virologist said it was time to deepen multisectoral partnerships and expand Nigeria’s preparedness to scale access to the vaccine, once approved.
She explained that “the development of any successful vaccine takes time, determination, and many contributors,” stressing that the
Bill and Melinda Gates group would lead development of the vaccine candidate and sponsor future clinical tests.
The Gates group is leading the development of the vaccine candidate and has committed to sponsoring future clinical tests in conjunction with London based Glaxo.
Philip Thomson, Glaxo’s President for Global Affairs, said “with such alliances, we can take a more sustainable approach to global health.
“We shall focus more efforts and expertise on science and research, while partnering with others to ensure development and delivery.”
Glaxo has been involved in product development programmes to focus on the most lucrative opportunities, such as cancer drugs.
The company offloaded its vaccines against Ebola virus to the Sabin Vaccine Institute in August.
The vaccine contains an engineered protein that is modeled on those of tuberculosis.
It is boosted with the company’s AS01 adjuvant, which is designed to heighten the body’s immune response and better prepare it for bacterial infection.
Edited By: Hadiza Mohammed-Aliyu
Watch Live News
Make A Comment
- COVID-19: Gombe Govt. suspends N30,000 minimum wage, slashes political appointees salaries
- Covid-19: Taraba govt. announces interstate travel ban
- COVID-19: FRSC sensitises drivers on social distancing
- COVID-19: Rivers residents lament hike on prices of consumables
- COVID-19: Plateau United urges fans to adhere to government’s directives
- Senate President felicitates with Tinubu at 68
- COVID-19 : Gov. Ganduje flags off fumigation of public places
- Military neutralises several terrorists, destroys their logistics facilities in Sambisa forest
- COVID – 19 : Adamawa Govt dismisses curfew rumor
- COVID-19: C/River bans religious gatherings of more than 5 persons